Disorder of eye
Beacon’s rare eye disease gene therapy signals vision function improvements in early phase 2 data
XLRP, gene therapy, laru-zova, visual function, rare eye disease, Phase 2 trial, DAWN trial, vision improvement, low light vision
J&J’s $130M gene therapy bet flunks rare retinal disease trial
Johnson & Johnson, gene therapy, bota-vec, X-linked retinitis pigmentosa, Phase 3 failure, vision loss treatment, rare eye disease, $130 million investment